Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623671 | 0.84 | AR (0.39) | GABRA2GABRB2ARKDM4E | |
| SCHEMBL19704560 | 0.83 | DPP4 (0.32) | GABRA2GABRB2DPP4 | |
| SCHEMBL25511448 | 0.82 | AR (0.31) | GABRA2GABRB2AR | |
| SCHEMBL18812323 | 0.82 | GABRA2 (0.37) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL27019753 | 0.82 | GABRA2 (0.37) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL18623676 | 0.82 | AR (0.49) | GABRA2GABRB2ARCA12CA9 | |
| SCHEMBL18812340 | 0.82 | AR (0.31) | GABRA2GABRB2AR | |
| SCHEMBL15491906 | 0.82 | AR (0.31) | GABRA2GABRB2DPP4AR | |
| SCHEMBL22030529 | 0.82 | GABRA2 (0.37) | GABRA2GABRB2DPP4HRH4HRH3 | |
| SCHEMBL25983001 | 0.82 | GABRA2 (0.37) | GABRA2GABRB2DPP4HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-11912709-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | UNIVERSITY OF MASSACHUSETTS (US) | 2024-02-27 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111823-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111854-A1 | 1,2,4-TRIAZOLE ARYL N-OXIDES DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111824-A1 | AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-7335753-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070072811-A1 | Bifunctional heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GABRA2 89/4885GABRB2 77/4885DPP4 988/4885 |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | HIF1AN, HIF1A, HYOU1 | GABRA2 2868/4885GABRB2 2069/4885DPP4 4611/4885 |
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | GABRA2 3924/4885GABRB2 3746/4885DPP4 2249/4885 |
| US-20070072811-A1 | Bifunctional heterocyclic compounds and methods of making and using the same | PCNA, DCX, HPGDS | GABRA2 3484/4885GABRB2 3220/4885DPP4 2231/4885 |
| US-20090111854-A1 | 1,2,4-TRIAZOLE ARYL N-OXIDES DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GABRA2 83/4885GABRB2 71/4885DPP4 1812/4885 |
| US-11912709-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | PBRM1, MGMT, TOP1 | GABRA2 3163/4885GABRB2 3281/4885DPP4 4766/4885 |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GABRA2 107/4885GABRB2 97/4885DPP4 1065/4885 |
| US-20090111823-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM2 | GABRA2 82/4885GABRB2 88/4885DPP4 960/4885 |
| US-20090111824-A1 | AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GABRA2 69/4885GABRB2 64/4885DPP4 1666/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | GABRA2 4097/4885GABRB2 3316/4885DPP4 2641/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | GABRA2 4052/4885GABRB2 3575/4885DPP4 1861/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | GABRA2 2246/4885GABRB2 1724/4885DPP4 3330/4885 |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | GABRA2 2182/4885GABRB2 2467/4885DPP4 1668/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | GABRA2 4686/4885GABRB2 4576/4885DPP4 3759/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | GABRA2 2272/4885GABRB2 2209/4885DPP4 591/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GABRA2 452/4885GABRB2 350/4885DPP4 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.